Figure 4
Apigenin improves glucose tolerance in miR103 transgenic mice.
(a), Expression levels of mature miR103, miR122 and miR185 in liver tissues of miR103 transgenic mice (miR103 Tg) were determined by Northern blotting. (b), Expression levels of mature miR103 and its precursor in liver tissues of miR10-transgenic mice treated with apigenin were determined by Northern blotting. Control (DMSO) or apigenin (40 mg/kg) was injected intraperitoneally daily for 14 days. Representative results from three independent mouse sets are shown. (c), Liver tissue homogenates from miR103 transgenic mice were separated using a phos-tag gel to determine the phosphorylation status of TRBP. Representative results from three independent mouse sets are shown. Full-length blot image is available in Supplementary Figure 5g. (d), Blood glucose levels were determined at random times or after 12 h fasting in control and miR103 transgenic (miR103 Tg) mice (n = 8 in each group). Data represent the means ± s.d. *, p < 0.05 (t-test). (e), (f), Glucose and pyruvate tolerance tests in control, miR103 transgenic (miR103 Tg) and miR103 transgenic with apigenin treatment (miR103 Tg + apigenin) mice (n = 6 in each group). Data represent the means ± s.d. *, p < 0.05 (t-test).
